In this issue:
OVERLORD MS: ocrelizumab vs. rituximab in relapsing MS
Relapse risk after MMR/varicella vaccination
Physical activity & MS disability progression
EBV infection & risk of MS
High-efficacy therapy initiation in childhood
Central autonomic network dysfunction in RRMS & progressive MS
MS & reduced income growth
EXPAND: siponimod & progression to wheelchair in SPMS
Ocrelizumab discontinuation & disease activity
Monoclonal antibodies & breastfeeding in MS/NMOSD
Please login below to download this issue (PDF)